Leukemia, lymphoma, and myeloma.

25 Phase 1 studies recruiting right now, most recently updated first.

Leukemia, lymphoma, and myeloma25 studies

Non Hodgkin LymphomaNCT07225439Papers

Tafasitamab

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Paolo Caimi, MDOpen the brief

Hairy Cell LeukemiaNCT04815356Papers

CD22CART cell

Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

National Cancer Institute (NCI)Open the brief

NeoplasmsNCT05836896Papers

MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

Technische Universität DresdenOpen the brief

Acute Myeloid Leukemia, PediatricNCT06158828

TCR alpha beta / CD19+ depleted haploidentical hematopoietic

Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Washington University School of MedicineOpen the brief

T-cell Acute Lymphoblastic LymphomaNCT03081910Papers

Autologous CD5.CAR/28zeta CAR T cells

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

Baylor College of MedicineOpen the brief

Multiple MyelomaNCT05976555Papers

BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)

BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Medical College of WisconsinOpen the brief

B-Cell LymphomaNCT05092451Papers

CAR.70/IL15-transduced CB-NK cells

CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer CenterOpen the brief

Recurrent Childhood Acute Myeloid LeukemiaNCT06609928Papers

FOLR1 CAR T-cells

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Fred Hutchinson Cancer CenterOpen the brief

B-Non Hodgkin LymphomaNCT05442515Papers

CD19/CD22-CAR-transduced T cells

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

National Cancer Institute (NCI)Open the brief

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1NCT01371630Papers

Inotuzumab Ozogamicin

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M.D. Anderson Cancer CenterOpen the brief

Non-Hodgkin LymphomaNCT05098613Papers

CD19x22 CAR T Cells

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

University of Colorado, DenverOpen the brief

Refractory Acute Myeloid LeukemiaNCT06017258Papers

CD371-specific/YSNVz/I-18 CAR T cells

CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Memorial Sloan Kettering Cancer CenterOpen the brief

Acute Lymphoblastic LeukemiaNCT03128034Papers

Cyclosporine

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Fred Hutchinson Cancer CenterOpen the brief

Acute Myeloid LeukemiaNCT04024761Papers

CIML NK

CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Dana-Farber Cancer InstituteOpen the brief

Acute Myeloid LeukemiaNCT03113643Papers

SL-401

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dana-Farber Cancer InstituteOpen the brief

Hodgkin's LymphomaNCT02917083Papers